Vanda Pharmaceuticals Inc.
imsidolimab
Generalized Pustular Psoriasis
Countdown
158days
FDA decision · Dec 12, 2026
What's at stake
The FDA's approval decision on imsidolimab for Generalized Pustular Psoriasis is due Dec 12, 2026. A green light opens the market; a complete response letter (CRL) usually sinks the stock.
Primary source
· SEC 8-K
verified 15h ago
“The FDA accepted the Biologics License Application (BLA) for imsidolimab in Generalized Pustular Psoriasis (GPP) with a Prescription Drug User Fee Act (PDUFA) target action date of December 12, 2026.”